"目錄號: HY-15204
Tonabersat 是一種gap-junction調(diào)節(jié)劑。
相關(guān)產(chǎn)品
生物活性
Description
Tonabersat is agap-junctionmodulator.
IC50& Target
Gap-junction[1]
In Vitro
Tonabersat, a novel benzopyran derivative, inhibits cortical spreading depression (CSD) and therefore might be able to inhibit the early migraine mechanisms[1].
In Vivo
Treatment with either Tonabersat (10 mg/kg) or Meclofenamate (20 mg/kg) as single agents significantly inhibit progression of metastatic lesions. Addition of carboplatin to either agent profoundly inhibits brain metastasis[2].
Clinical Trial
Minster Research Ltd
Migraine Without Aura-Migraine With Aura
April 2006
Phase 2
Minster Research Ltd
Migraine Without Aura-Migraine With Aura
October 2007
Phase 2
Minster Research Ltd-University of Copenhagen
Migraine With Aura
May 2006
Phase 2
View MoreCollapse
References
